Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IHC 2021 | The role of glutamatergic receptor activation in migraine

Anna Andreou, PhD, King’s College London, London, UK, talks on the role of glutamate as a treatment target for migraine. Glutamate involvement in migraine pathophysiology has been reported for many years. Dr Andreou explains that glutamate is the main excitatory neurotransmitter in the trigeminal pathway, which drives and modulates activation of the pain pathway. This interview took place during the International Headache Congress 2021.


Honoraria for educational purposes from AbbVie, Allergan, Eli Lilly, eNeura, Zenith Scientific.
Honoraria for advisory purposes from Allergan, Eli Lilly, eNeura, Neuresta, Zenith Scientific.
R&D funding from eNeura, Eli Lilly.
Sponsorship for educational purposes from Allergan, ATI, Eli Lilly, eNeura, Novartis.
Board member of GSConsulting, Neuresta.